Caribou Biosciences Share Price Today: Live Updates & Key Insights

Caribou Biosciences share price today is $1.6, up -3.68%. The stock opened at $1.62 against the previous close of $1.63, with an intraday high of $1.62 and low of $1.575.

Caribou Biosciences Share Price Chart

Caribou Biosciences

us-stock
To Invest in {{usstockname}}
us-stock

Caribou Biosciences Share Price Performance

$1.6 -0.0368(-3.68%) CRBU at 27 Jul 2026 02:32 PM Biotechnology
Lowest Today 1.575
Highest Today 1.62
Today’s Open 1.62
Prev. Close 1.63
52 Week High 3.54
52 Week Low 1.38
Day’s Range: Low 1.575 High 1.62
52-Week Range: Low 1.38 High 3.54
1 day return -
1 Week return -2.76
1 month return -5.67
3 month return -25.82
6 month return +3.26
1 year return -31.15
3 year return -76.22
5 year return -90.61
10 year return -

Caribou Biosciences Institutional Holdings

Pfizer Inc 4.73

Vanguard Group Inc 4.34

Vanguard Capital Management, LLC 3.80

Vanguard Total Stock Mkt Idx Inv 3.04

Renaissance Technologies Corp 2.61

Kynam Capital Management, LP 2.52

iShares Russell 2000 ETF 2.33

BlackRock Inc 2.16

ACATIS Datini Valueflex Fonds A 2.02

Two Sigma Investments LLC 1.77

Selectra J. Lamarck Biotech A 1.47

Bank of America Corp 1.31

Aberdeen Group PLC 1.22

Marshall Wace Asset Management Ltd 1.22

Two Sigma Advisers, LLC 1.12

Vanguard Institutional Extnd Mkt Idx Tr 1.12

Millennium Management LLC 1.08

Geode Capital Management, LLC 1.03

Partner Fund Management LP 0.97

Mackenzie Investments 0.95

Acadian Asset Management LLC 0.93

iShares Russell 2000 Value ETF 0.88

Susquehanna International Group, LLP 0.84

FMR Inc 0.73

Dimensional Fund Advisors, Inc. 0.68

Maverick Capital Ltd 0.66

iShares Biotechnology ETF 0.64

Vanguard Russell 2000 ETF 0.53

State St Russell Sm/Mid Cp® Indx SL Cl I 0.50

Mackenzie Quantitative US Small Cap 0.47

Fidelity Extended Market Index 0.45

Schwab US Small-Cap ETF™ 0.43

State St Russell Sm Cap® Idx SL Cl I 0.34

iShares Micro-Cap ETF 0.31

Mackenzie GQE US Small Cap F8 0.31

Galileo - Biotech Innovation Fund S USD 0.30

Dimensional US Small Cap ETF 0.26

Bruce 0.25

NT R2000 Index Fund - NL 0.21

Extended Equity Market Fund E 0.21

Caribou Biosciences Market Status

Strong Buy: 5

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Caribou Biosciences Fundamentals

Market Cap 161.66 M

PB Ratio 1.5847

PE Ratio 0.0

Enterprise Value 70.98 M

Total Assets 175.37 M

Volume 946833

Caribou Biosciences Company Financials

Annual Revenue FY23:34611000 34.6M, FY22:13851000 13.9M, FY21:9598000 9.6M, FY20:12361000 12.4M, FY19:5788000 5.8M

Annual Profit FY23:null 0.0M, FY22:13851000 13.9M, FY21:9598000 9.6M, FY20:12361000 12.4M, FY19:5788000 5.8M

Annual Net worth FY23:-94554000 -94.6M, FY22:-99421000 -99.4M, FY21:-66923000 -66.9M, FY20:-34308000 -34.3M, FY19:-23431000 -23.4M

Quarterly Revenue Q1/2026:2397000 2.4M, Q3/2025:2198000 2.2M, Q2/2025:2667000 2.7M, Q1/2025:2353000 2.4M, Q3/2024:2024000 2.0M

Quarterly Profit Q1/2026:1748000 1.7M, Q3/2025:1567000 1.6M, Q2/2025:2667000 2.7M, Q1/2025:2353000 2.4M, Q3/2024:2024000 2.0M

Quarterly Net worth Q1/2026:-25085000 -25.1M, Q3/2025:-27548000 -27.5M, Q2/2025:-54098000 -54.1M, Q1/2025:-39991000 -40.0M, Q3/2024:-34684000 -34.7M

About Caribou Biosciences & investment objective

Company Information Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Organisation Biotechnology

Employees 97

Industry Biotechnology

CEO Dr. Rachel E. Haurwitz Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Caribou Biosciences FAQs

What is the share price of Caribou Biosciences today?

The current share price of Caribou Biosciences is $1.6.

Can I buy Caribou Biosciences shares in India?

Yes, Indian investors can buy Caribou Biosciences shares by opening an international trading and demat account with Motilal Oswal.

How to buy Caribou Biosciences shares in India?

You can easily invest in Caribou Biosciences shares from India by:

Can I buy fractional shares of Caribou Biosciences?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Caribou Biosciences?

Caribou Biosciences has a market cap of $161.66 M.

In which sector does Caribou Biosciences belong?

Caribou Biosciences operates in the Biotechnology sector.

What documents are required to invest in Caribou Biosciences stocks?

To invest, you typically need:

What is the PE and PB ratio of Caribou Biosciences?

The PE ratio of Caribou Biosciences is N/A and the PB ratio is 1.58.